As I watched a two-hour television special about the highlights of 2013, I was reminded of just how remarkable the year was – full of milestones, tragedies and celebrations. And, I’m sure each of us have those special memories that surface to the top. Even the simple, yet so impactful, “pay it forward” initiative is right near the top for me. I can still remember how I felt when I pulled up to pay for my coffee at the Starbucks drive-thru window and was told “there is no charge sir, the car before you paid!” WOW! Me? Mine?! That person didn’t even know me?
Without question, 2013 was a year of milestones, tragedies and celebrations for the Kanzius Cancer Research Foundation as well. It’s important to reflect back on the past year as we embark upon the bright possibilities of 2014.
We hit the ground running with the national release of our first PSA entitled “A Better Way” that featured six individuals who have, in some way, been affected by cancer. Filmed at the faces2012 national conference, Erie-based R. Frank Photography generously donated their time to record and edit the production. “A Better Way” aired in mid-January on DishTV and sparked more interest than ever in our mission for a side-effect free cancer treatment.
On February 15th, the scientific journal Biomaterials published a manuscript compiled by our lead investigator, Dr. Steven Curley and his research team summarizing numerous studies that show that the Kanzius radio frequency (RF) field can be used to release drugs from carbon nanoparticles; a very important proof of principle. These studies proved that the act of releasing non-toxic peptides (proteins) to increase the heat sensitivity of cancer cells may be possible.
Along this road of promising scientific progress, we never lose sight of what is truly important and what the foundation’s ultimate goal is. “Our number one priority is to get this promising technology in front of the FDA, and we are committed to moving forward and overcoming any barriers and obstacles that might come into the path of our success,” said Dr. Curley in his spring research update. “Reaching the FDA is our #1 priority.”
The Kanzius Foundation announced on May 10th the commencement of the “Million Dollar Challenge;” a fundraising effort celebrating an anonymous $1 million donation contingent upon our raising an additional $250,000 from current and $250,000 from new donors. You accepted this challenge and, in ten short weeks, helped us raise over $1.5 million for our research and propelling us even closer to reaching the dream of John Kanzius: “a better way” to treat cancer.
After months of calibration and intricate preparation, tests using the GenV Kanzius Device (a human-sized machine) began with a controlled group of large, non-human laboratory subjects. The preliminary outcomes demonstrated that the RF treatment administered to the lab subjects through our GenV Device was not only effective in killing 100% of the liver cancer cells, but was also side-effect free with no toxic or damaging results seen in the neighboring tissues.
While on a visit to our Houston labs in October, Dr. Curley, revealed that as a result of the successful large animal studies, the Kanzius Noninvasive Radiowave Cancer Treatment was nearing human trials. He announced that ThermMed LLC, started by the late John Kanzius had completed negotiations with a new group to transfer the ownership of the intellectual properties (patents). “The new company will help support the research, but they are also very goal directed at getting in front of the FDA,” Curley shared. The Kanzius research team is preparing to approach the FDA in early 2014 and the treatment could advance to human trials as early as 2015.
As our research team makes the necessary preparations, the promising research advancements of 2013 make us hopeful that this meeting with the FDA will pave the way for human trials with immediacy and urgency. We know so many are depending on this.
So, we welcome you 2014 with great anticipation! And I pray that my forecast is correct – that your commitment to “a better way” will be rewarded – that we can advance to the FDA and beyond. Because, each time you donate to Kanzius Cancer Research Foundation, it is really not for you. It is your way to “pay it forward” for that unknown person who is in desperate need for the promising outcomes of OUR cancer research. And for that, I say thank you from each of them!
MARK A. NEIDIG SR. is executive director of the Kanzius Cancer Research Foundation (MNeidig@Kanzius.org).